Eurobio-Scientific Stock: price and insider trades · France

From a product standpoint, Eurobio Scientific offers a diversified range of diagnostic and research solutions. Its portfolio includes molecular biology assays, infectious-disease test panels, autoimmunity solutions, culture media, and products for corneal graft transport and preservation. The company also distributes instruments and reagents for life-science research laboratories. This mix of proprietary and distributed products is an important competitive strength, supporting both differentiation and recurring revenues.

Eurobio Scientific positions itself as a leading player in the French specialty IVD market, while maintaining a meaningful international footprint. The group is headquartered in the Paris region and has subsidiaries or affiliates in the United States, notably in San Diego and Chicago, as well as across several European countries including the UK, Germany, Switzerland, Belgium, the Netherlands and Italy. In 2024, international markets accounted for 41% of group revenue, confirming the company’s growing geographic diversification.

Financially, 2024 highlighted the resilience of the core business, with revenue rising to €154.2 million, up 19%, and positive cash generation. Eurobio Scientific has also continued to execute a growth-by-acquisition strategy, including the EndoPredict oncology test and recent initiatives aimed at strengthening its transplantation franchise. Overall, the group’s strategic direction is clear: to build a larger, more proprietary and more international specialty diagnostics platform with a stronger position in high-value clinical niches.